20 November 2024 Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million Download Presentation Webcast Workbook
14 November 2024 Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024 Download Presentation Webcast Workbook
5 November 2024 Invitation to Scandion Oncology webcast and conference call November 11, 2024 Download Presentation Webcast Workbook
4 November 2024 Scandion Oncology announces the start of the exercise period for warrants of series TO 2 Download Presentation Webcast Workbook
31 October 2024 Correction: Scandion Oncology announces exercise price for warrants of series TO 2 Download Presentation Webcast Workbook
30 October 2024 Scandion Oncology announces exercise price for warrants of series TO 2 Download Presentation Webcast Workbook
19 August 2024 Scandion Oncology strengthens partnering outreach Download Presentation Webcast Workbook
16 August 2024 Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3 Download Presentation Webcast Workbook
11 July 2024 SCANDION ONCOLOGY’S RIGHTS ISSUE REGISTERED WITH THE DANISH BUSINESS AUTHORITY Download Presentation Webcast Workbook
1 July 2024 Scandion Oncology board member Michel Ducreux steps down, joins advisory board Download Presentation Webcast Workbook
25 June 2024 SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE Download Presentation Webcast Workbook
3 June 2024 Scandion announces change of Certified Adviser to Vator Securities Download Presentation Webcast Workbook